

type of report	Current report
number	34/2012
date of publication	2012-07-20 13:29:34
company	PHARMENA

Obtaining a patent in Japan

The Management Board of PHARMENA S.A. declares that on 20th July 2012, it received notification that it was granted a patent no. 2006-548308 by Japan Patent Office. The patent will provide protection for the use of 1-methylnicotinamide (1-MNA) in the treatment of lipid profile disorders on Japanese market. Pharmena S.A., via its subsidiary company Cortria Corporation, conducts research in USA and Canada on innovative anti-atherosclerotic medicinal product based on active substance 1-MNA. Obtaining of the above patent enhances territorial patent protection of 1-MNA, which belongs to PHARMENA S.A. Previous patents applied to, among others, the territory of USA, Canada, Europe, Australia, Russia, Mexico, and China.

The information is made public due to the fact that possessing patents and patent applications for the use of active substances owned by PHARMENA S.A. may influence market valuation of the company PHARMENA S.A., as well as due to participation in potential revenue resulting from commercialisation of the above patents and patent applications.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board